Dr Alastair  O'Brien studied medicine at Guy's and St Thomas' Hospitals and qualified in 1994. He underwent specialist training in liver disease, gastroenterology and general medicine in London. He was appointed as a Clinical Senior Lecturer at University College London in 2007.

Dr O'Brien was a Medical Research Council clinical training fellow and completed his PhD thesis under Professor Mervyn Singer at UCL. This work led to a landmark paper on the use of terlipressin as rescue therapy for norepinephrine-resistant septic shock that was published in the Lancet.

Continuing his research work at the university allows Dr O'Brien to bring his patient the latest treatments available to ensure a positive outcome.

Infection is the most serious problem facing patients with advanced liver cirrhosis and Dr O'Brien's pioneering work alongside Professor Gilroy at UCL has led the exciting discovery that Prostglandin E2 mediates white cell dysfunction in these patients. This was published in Nature Medicine 2014. We hope that our Wellcome Trust and Department of Health funded clinical trial across 40 sites and involving 900 patients will lead to improved survival rates. We have completed the feasibilty study and will report on this early summer 2016.

I currently hold grants as Principal or Co-Investigator from the Wellcome Trust, Medical Research Council and Department of Health.

I lead a laboratory based research group and clinical trial team as well as my clinical duties 

Dr O'Brien is registered with BUPA, Simply Health, AXAPPP, Cigna and PRUhealth